Literature DB >> 11334873

Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed.

V Ralevic1, D A Kendall.   

Abstract

The present study investigated whether cannabinoids can modulate neurotransmission mediated by capsaicin-sensitive sensory nerves in the rat isolated mesenteric arterial bed. Sensory neurogenic vasorelaxation mediated by electrical field stimulation was concentration-dependently attenuated by HU210 (0.1-3 microM), a cannabinoid receptor agonist (from 62+/-8.3% to 6+/-2.1% at 3 microM HU210). HU210 had no effect on relaxation to exogenous calcitonin gene-related peptide, indicating a prejunctional action. The action of HU210 (1 microM) was not affected by LY320135 (1 microM) or SR144528 (1 microM), cannabinoid CB(1) and CB(2) receptor antagonists, respectively. SR141716A (0.01-1 microM), a cannabinoid CB(1) receptor antagonist, concentration-dependently augmented vasorelaxation to electrical field stimulation, but had no effect on responses to calcitonin gene-related peptide and capsaicin, indicating a possible role of endogenous cannabinoids in sensory neurotransmission in rat mesenteric arteries. These data show that the cannabinoid receptor agonist HU210 inhibits prejunctionally sensory neurotransmission in rat mesenteric arteries and that this action is independent of cannabinoid CB(1)- or CB(2)-like receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334873     DOI: 10.1016/s0014-2999(01)00940-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].

Authors:  S Ständer; H W Reinhardt; T A Luger
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  Cannabinoid control of neurogenic inflammation.

Authors:  Meagan McKenna; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

3.  Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons.

Authors:  Nathaniel A Jeske; Amol M Patwardhan; Nikita Gamper; Theodore J Price; Armen N Akopian; Kenneth M Hargreaves
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

Review 4.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

Authors:  R White; W S Ho; F E Bottrill; W R Ford; C R Hiley
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed.

Authors:  J D Wilkinson; D A Kendall; V Ralevic
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

7.  Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.

Authors:  Marnie Duncan; Paul Millns; Darren Smart; James E Wright; David A Kendall; Vera Ralevic
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

8.  Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Authors:  P M Hoi; C Visintin; M Okuyama; S M Gardiner; S S Kaup; T Bennett; D Baker; D L Selwood; C R Hiley
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

9.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 10.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.